Infectious Diseases in Obstetrics and Gynecology 1:59 (1993)
1993
Controversies Surrounding Group B Streptococcus Screening in Pregnant Patients
Editorial
Author Information
Author(s): Sebastian Faro
Conclusion
Universal screening for Group B Streptococcus in pregnant patients should be delayed until more accurate and cost-effective testing methods are developed.
Supporting Evidence
- Universal screening for Group B Streptococcus is controversial and not universally agreed upon.
- Current rapid tests for Group B Streptococcus have a significant false-negative rate.
- False-positive tests can lead to unnecessary antibiotic treatments, posing risks to patients.
Takeaway
Doctors are debating whether all pregnant women should be tested for a germ called Group B Streptococcus, but they need better tests before making that decision.
Potential Biases
Legal pressures may influence medical recommendations and practices.
Limitations
Current tests for detecting Group B Streptococcus are inaccurate and can lead to unnecessary treatments.
Want to read the original?
Access the complete publication on the publisher's website